Weiguo Qing

机构：Shanghai University of Medicine and Health Sciences

发表论文 38 篇 · 总被引 1455 次 · h-index 11

代表论文

• Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy (2014 · Cancer Biology & Therapy · 被引 157)
• Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models (2014 · Molecular Oncology · 被引 122)
• Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation (2016 · Oncotarget · 被引 38)
• Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor (2019 · European Journal of Pharmaceutical Sciences · 被引 23)
• Abstract 2089: Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models (2017 · Cancer Research · 被引 7)
• Abstract 4187: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF1R kinases (2017 · Cancer Research · 被引 6)